Alternative Data for ANI Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 35 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 102 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,145 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 688 | Sign up | Sign up | Sign up |
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
| Price | $78.01 |
| Target Price | Sign up |
| Volume | 1,307,703 |
| Market Cap | $1.77B |
| Year Range | $70.49 - $98.81 |
| Dividend Yield | 0% |
| PE Ratio | 19.95 |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ETApril 24 - GlobeNewswire |
|
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release CapsulesApril 13 - GlobeNewswire |
|
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in OphthalmologyApril 7 - GlobeNewswire |
|
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf.March 3 - Yahoo Entertainment |
|
ANI Pharmaceuticals to Present at Upcoming Investor ConferencesFebruary 24 - GlobeNewswire |
|
 |
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 13 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 237M | 0 | 0 | 29M | 57M | 2.050 |
| Q4 '25 | 247M | 9.5M | 238M | 27M | 77M | 2.330 |
| Q3 '25 | 228M | 116M | 112M | 24M | 61M | 2.040 |
| Q2 '25 | 211M | 75M | 137M | 8.5M | 39M | 0.360 |
| Q1 '25 | 197M | 73M | 124M | 16M | 48M | 0.690 |
Insider Transactions View All
| Cook Meredith filed to sell 78,390 shares at $78.2. May 13 '26 |
| Walsh Patrick D filed to sell 38,432 shares at $80.6. May 13 '26 |
| Rowland Thomas Andrew filed to sell 38,271 shares at $79.2. May 13 '26 |
| Gutwerg Ori filed to sell 78,696 shares at $79.5. May 13 '26 |
| Walsh Patrick D filed to sell 48,432 shares at $80.8. May 13 '26 |
Similar companies
Read more about ANI Pharmaceuticals (ANIP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - ANI Pharmaceuticals
The Market Cap of ANI Pharmaceuticals is $1.77B.
As of today, ANI Pharmaceuticals' PE (Price to Earnings) ratio is 19.95.
Currently, the price of one share of ANI Pharmaceuticals stock is $78.01.
The ANIP stock price chart above provides a comprehensive visual representation of ANI Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ANI Pharmaceuticals shares. Our platform offers an up-to-date ANIP stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, ANI Pharmaceuticals (ANIP) does not offer dividends to its shareholders. Investors interested in ANI Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of ANI Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
